Therapeutic agent for hematopoietic tumors
An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.
1. A pharmaceutical composition for the treatment of leukemia, wherein the active ingredient of the pharmaceutical composition consists of the IRF-2 protein and a cytotoxic antibody wherein the antibody is any one of the following antibodies:
a) the anti-HM1.24 antibody produced by the hybridoma having the Deposit No. FERM BP-5233;
b) a chimeric antibody of the anti-HM1.24 antibody of a); and
c) a humanized antibody of the antibody of the anti-HM1.24 antibody of a).
2. The pharmaceutical composition according to claim 1 wherein said leukemia is acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphocytic leukemia, or chronic lymphocytic leukemia.
3. The pharmaceutical composition according to claim 1 wherein said cytotoxicity is ADCC activity.
4. The pharmaceutical composition of claim 1 , wherein the chimeric or humanized antibody comprises a human antibody constant region Cγ.
5. The pharmaceutical composition of claim 4 , wherein the human antibody constant region Cγ is a Cγ1 or Cγ3 constant region.